Boston, MA 06/19/2014 (wallstreetpr) – Gilead Sciences, Inc. (NASDAQ:GILD) was having the best of times from last some months. But now it seems the real problem for the company is soon going to start. Its Sovaldi treatment is at the risk of rejection from the U.K. Cost Regulators. The regulator has made it clear that it can reject the $60,000 hepatitis C drug treatment. It will look out for details and will then decide over the matter. Accordingly, it will be decided if British government will pay for the treatment or not.
The Problem Mounts
Sovaldi drug treatment got the approval in January. The success rate was as high as 90%. It increased the chances of curing the disease. But recently the news is the effectiveness of drugs is not clearly visible on some patient’s group. It is a great problem for Gilead Sciences, Inc. (NASDAQ:GILD). It is said by the National Institute for Health and Care Excellence. It has demanded the clear evidences from the company about the cost effectiveness of Sovaldi treatment along with its side effects on the other parts of the body. The company is already facing a lot more problems and oppositions due to the high pricing of Sovaldi treatment. Now it has become imperative for a company to prove that Gilead is a cost effective treatment.
The Company’s View
Gilead Sciences, Inc. (NASDAQ:GILD) has made it cleared that it would come up with all the evidence requested by the commission. The company is sure to get a positive recommendation. It has got the time till July 4 to come up with the proper evidences. Gilead should make sincere efforts as the effect of the drug is seen on the patients. The medical world needs good drugs, and Sovaldi is becoming one of them. The sales of Sovaldi are expected to cross $9 billion in this year.
